METHODS : We did a retrospective individual data analysis based on all published randomised trials that included treatment-naive patients with BRAF ( V600E ) - mutant or BRAF ( V600K ) - mutant metastatic melanoma who received the approved dose of dabrafenib 150 mg twice daily plus trametinib 2 mg once daily .